Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Lischer

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Haematologica|June 27, 2024
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamabAlexander Biedermann, Maria Patra-Kneuer, Dimitrios Mougiakakos, et al.
Blood|May 7, 2025
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCTCindy Sheree Flamann, Haroon Shaikh, Carina Matos, et al.
Leukemia|April 17, 2024
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR<sup>low/neg</sup> monocytes in lower-risk myelodysplastic neoplasmsSusann Winter, Marie Schneider, Uta Oelschlaegel, et al.
Cancer Immunology Research|February 10, 2021
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated MacrophagesDimitrios Mougiakakos, Christian Bach, Martin Böttcher, et al.
Blood Advances|October 7, 2022
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapyHannah Reimann, Anita N Kremer, Viktoria Blumenberg, et al.
Journal for Immunotherapy of Cancer|May 9, 2024
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapyChristopher Lischer, Martin Eberhardt, Cindy Flamann, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Haematologica|June 27, 2024
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamabAlexander Biedermann, Maria Patra-Kneuer, Dimitrios Mougiakakos, et al.
Blood|May 7, 2025
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCTCindy Sheree Flamann, Haroon Shaikh, Carina Matos, et al.
Leukemia|April 17, 2024
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR<sup>low/neg</sup> monocytes in lower-risk myelodysplastic neoplasmsSusann Winter, Marie Schneider, Uta Oelschlaegel, et al.
Cancer Immunology Research|February 10, 2021
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated MacrophagesDimitrios Mougiakakos, Christian Bach, Martin Böttcher, et al.
Blood Advances|October 7, 2022
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapyHannah Reimann, Anita N Kremer, Viktoria Blumenberg, et al.
Journal for Immunotherapy of Cancer|May 9, 2024
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapyChristopher Lischer, Martin Eberhardt, Cindy Flamann, et al.
Pageof 2